Bazedoxifene Acetate Formulations Preventing Polymorphic Conversion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in preventing or minimizing polymorphic conversion of bazedoxifene acetate from one crystalline form to another during pharmaceutical formulation and storage, as this affects stability, solubility, and pharmacokinetics, with existing methods like wet granulation potentially increasing conversion rates.
Innovation Solution
The development of pharmaceutical compositions using a non-aqueous process such as direct blending or dry granulation to prepare bazedoxifene acetate predominantly in the A polymorph form, reducing the likelihood of conversion to the more stable but less soluble Form B, thereby maintaining the advantages of a single polymorphic form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wet granulation process is used to prepare bazedoxifene acetate formulations, then manufacturing efficiency is improved, but polymorphic conversion from Form A to Form B increases
Solution Approach 1:
The patent changes the fundamental parameter of the granulation process from wet to dry, eliminating water as a solvent. This parameter change prevents the dissolution-recrystallization cycle that causes polymorphic conversion, while still enabling formulation processing and manufacturing efficiency through dry granulation techniques.
Solution Approach 2:
The patent extracts and removes water from the granulation process entirely. By eliminating the aqueous environment, the patent prevents the mechanism by which polymorphic conversion occurs (dissolution in water followed by recrystallization), thereby maintaining polymorphic stability while allowing formulation to proceed.
2Stability of the object's composition
If Form B is produced due to polymorphic conversion, then thermodynamic stability is improved, but solubility decreases
Solution Approach 1:
The patent takes preliminary action to prevent polymorphic conversion before it can occur. By using a dry granulation process from the outset, the patent prevents the formation of Form B entirely, thereby preserving both the solubility advantages of Form A and avoiding the need for later polymorph control measures.
3Stability of the object's composition
If polymorphic conversion is allowed to occur during storage, then the drug reaches a more stable form, but shelf-life and therapeutic efficacy are reduced
Solution Approach 1:
The patent creates an inert environment by eliminating water from the formulation process. This anhydrous environment prevents the polymorphic conversion mechanism during both manufacturing and storage, thereby maintaining Form A stability throughout the drug's shelf-life and preserving therapeutic efficacy.
Data Source
AI summary
Bazedoxifene acetate formulations and compositions thereof having improved properties relating to reduction, elimination, or prevention of polymorphic conversion of bazedoxifene acetate, and processes for making such formulations and compositions. Components used in the formulations and compositions include a filler/diluent, an optional second filler/diluent, an optional antioxidant, a glidant/disintegrant, and a lubricant.